(Q36691749)

15 August 2017

1 reference

title

Spectrum of effectiveness of valproate in neuropsychiatry (English)

1 reference

15 August 2017

Charles L Bowden

1

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

9-16

1 reference

Valproate in the treatment of acute mania. A placebo-controlled study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Incorporation of [3H]valproic acid into lipids in GT1-7 neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

An overview of recent findings of the Stanley Foundation Bipolar Network (Part I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Search for a common mechanism of mood stabilizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

A role for protein kinase C and its substrates in the action of valproic acid in the brain: implications for neural plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

In psychosis, cortical interneurons overexpress DNA-methyltransferase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Acute and maintenance treatment with mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Maintenance efficacy of divalproex in the prevention of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

The use of divalproex in alcohol relapse prevention: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.9

21 January 2018

Identifiers

DOI

10.1586/14737175.7.1.9

1 reference

15 August 2017

1 reference